Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

UBS Upgrades Biogen to Buy, Announces $463 Price Target

UBS analyst Colin Bristow upgrades Biogen (NASDAQ:BIIB) from Neutral to Buy and announces $463 price target.
byBenzinga Newsdesk
June 10, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

UBS analyst Colin Bristow upgrades Biogen (NASDAQ:BIIB) from Neutral to Buy and announces $463 price target.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0